Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $97,888.70 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $97,888.70. Following the sale, the chief financial officer now owns 226,097 shares in the company, valued at approximately $2,057,482.70. The trade was a 4.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Mineralys Therapeutics Stock Up 7.8 %

Mineralys Therapeutics stock opened at $9.83 on Thursday. Mineralys Therapeutics, Inc. has a 52-week low of $7.95 and a 52-week high of $16.91. The firm’s fifty day moving average is $12.37 and its 200 day moving average is $12.49.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Monday, November 11th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30). During the same quarter in the previous year, the company earned ($0.57) EPS. Equities research analysts expect that Mineralys Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a report on Tuesday, November 12th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. raised its stake in shares of Mineralys Therapeutics by 17.7% in the third quarter. Franklin Resources Inc. now owns 1,745,513 shares of the company’s stock valued at $21,138,000 after acquiring an additional 262,922 shares during the period. Barclays PLC grew its holdings in Mineralys Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 38,218 shares of the company’s stock valued at $463,000 after purchasing an additional 28,208 shares during the last quarter. Geode Capital Management LLC raised its position in Mineralys Therapeutics by 6.6% in the 3rd quarter. Geode Capital Management LLC now owns 620,853 shares of the company’s stock worth $7,520,000 after purchasing an additional 38,527 shares during the period. Wellington Management Group LLP bought a new stake in Mineralys Therapeutics in the third quarter worth about $775,000. Finally, State Street Corp boosted its position in shares of Mineralys Therapeutics by 4.0% during the third quarter. State Street Corp now owns 483,766 shares of the company’s stock valued at $5,858,000 after buying an additional 18,627 shares during the period. 84.46% of the stock is owned by hedge funds and other institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.